Adamis Pharmaceuticals Corporation

11683 El Camino Real, Suite 300

San Diego, CA 92103

July 26, 2023

VIA EDGAR

Securities and Exchange Commission

Division of Corporation Finance

Office of Life Sciences

100 F Street, N.E.

Washington, D.C. 20549

To Whom it May Concern:

Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Adamis Pharmaceuticals Corporation (the "Company") hereby requests that the effective date of the above referenced registration statement (the “Registration Statement”) be accelerated to July 28, 2023, at 9:00 a.m., Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Weintraub Tobin Chediak Coleman Grodin, law corporation, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its obligations under the Securities Act of 1933, as amended.

Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Weintraub Tobin, by calling Kevin Kelso at (916) 558-6110.